Sniper and Otapiapia: Nigeria’s Organophosphate Poisoning Crisis Kills Nearly One in Four Patients

Organophosphate pesticides, the workhorses of agriculture across the developing world, are also among the deadliest chemicals routinely found in Nigerian homes and markets. A new systematic review published in Discover Toxicology has pulled together the scattered clinical evidence on acute organophosphate poisoning in Nigeria, synthesising data from 23 studies and 176 documented cases into the most comprehensive national picture to date. The findings are stark: nearly one in four patients died, children bore the brunt of accidental exposure, and the antidotes that could save lives were frequently out of reach.

The review, conducted by researchers at Obafemi Awolowo University in Ile-Ife, followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and searched PubMed, African Journals Online, Scopus and Google Scholar for studies published between January 2000 and August 2025. After screening 322 records and assessing 40 full-text articles, the team retained 23 studies comprising retrospective clinical reviews, case reports, case series and prospective reviews conducted predominantly in tertiary hospitals across Nigeria’s geopolitical zones. Individual study sizes ranged from a single patient to 31 organophosphate-specific cases, and the pooled analysis covered demographics, exposure circumstances, clinical features, treatment and outcomes.

The toxicology underpinning these cases is well characterised. Organophosphate compounds exert their lethal effect primarily through irreversible inhibition of acetylcholinesterase, the enzyme that breaks down the neurotransmitter acetylcholine. When the enzyme is disabled, acetylcholine accumulates at synapses and neuromuscular junctions, overstimulating muscarinic, nicotinic and central nervous system receptors. The result is an acute cholinergic crisis: pinpoint pupils, torrential salivation and lacrimation, bronchospasm, vomiting, diarrhoea, muscle fasciculations, seizures, loss of consciousness and, ultimately, respiratory failure. Recent research also points to secondary mechanisms, including neuroinflammation, oxidative stress and delayed neurological syndromes, that extend the damage well beyond the initial cholinergic storm.

In Nigeria, the compounds driving this crisis are largely domestic rather than agricultural in origin. The review identified Sniper, a dichlorvos-based insecticide sold over the counter, and Otapiapia, a locally produced organophosphate rodenticide, as the dominant agents, with chlorpyrifos also appearing. Sniper prevails in southern cities such as Lagos and Enugu, while Otapiapia dominates in the north, including Kano. Ingestion was by far the most common route of exposure, with dermal and inhalational cases rare. The ready availability of these products, often decanted into beverage containers or stored within easy reach of children, emerged as a recurring theme in the underlying studies.

Demographically, the review revealed a striking bimodal pattern of vulnerability. Of the 132 cases in which sex was reported, 72 were male and 60 female, a male-to-female ratio of roughly 1.2 to 1. Children accounted for 55 percent of all cases, and accidental ingestion predominated overall, making up 60.3 percent of the 131 cases with known circumstances. Almost all accidental poisonings occurred in young children, driven by curiosity and unsafe storage practices. Intentional poisoning, which accounted for 39.7 percent of cases, clustered among adolescents and young adults and was frequently linked to academic pressure, family conflict and emotional distress. One cited study described two 13-year-old girls who ingested pesticide in an apparent expression of rage toward their families, a detail that underscores the psychological dimensions of the problem.

Clinically, miosis, excessive salivation and lacrimation were the most consistently documented signs, while the prevalence of seizures varied between 4.9 and 23.1 percent across studies. Loss of consciousness and coma were common, and respiratory involvement was particularly ominous: one study reported dyspnoea in 33.3 percent of patients, while another recorded respiratory failure in as many as 84.6 percent. Vomiting, diarrhoea, tachycardia, bradycardia and hypotension appeared repeatedly, and one atypical presentation, sudden anosmia following Otapiapia exposure, was documented in northern Nigeria. Fasciculations and peripheral weakness, hallmarks of nicotinic involvement, were reported less frequently, possibly reflecting gaps in neurological documentation.

Management revealed the sharpest inequities. Atropine, the muscarinic antagonist that counters the cholinergic crisis, was the mainstay of treatment and was reported in 12 of the 23 studies. Pralidoxime, the oxime that can reactivate inhibited acetylcholinesterase if given early, appeared in only two studies, reflecting widespread unavailability. In one intensive care case, pralidoxime had to be sourced from abroad and was not administered until the seventh day, far beyond the window in which it is most effective. Decontamination with gastric lavage or skin washing, intravenous fluids, oxygen, antibiotics and electrolyte correction formed the supportive backbone, with mechanical ventilation reserved for the severely poisoned in tertiary centres. One resourceful team reported using exchange blood transfusion in a patient with severe poisoning and aspiration pneumonitis, an example of the improvisation forced by limited resources.

The pooled case fatality rate was 23.9 percent, with 42 deaths among 176 cases. Recovery rates were high among children with accidental ingestion, whereas intentional cases in adolescents and adults fared worse. Mortality was driven principally by respiratory failure and delayed presentation, compounded by the use of home remedies such as palm oil, raw eggs, milk, honey, coconut water and herbal mixtures, which families and traditional healers administer in the mistaken belief that they neutralise the poison. These interventions carry no evidence of benefit, may increase aspiration risk in unconscious patients, and delay hospital arrival, a factor the review identifies as directly linked to worse outcomes. Financial barriers also forced some families to discharge patients against medical advice, and intensive care admission, documented in at least seven cases, remained constrained by cost and scarcity.

Geography added another layer of complexity. Seventy percent of reported cases, 124 of 176, originated in southern Nigeria, with the South-West zone alone contributing 74 cases, or 42 percent of the total. The authors caution that this concentration likely reflects differences in research productivity, tertiary hospital density and publication access rather than a true north-south divide in poisoning frequency, noting that health research output in Nigeria is itself skewed toward the south. Comparable patterns in China, India, Nepal and Sri Lanka show that reported poisoning loads track agricultural pesticide use, but the Nigerian distribution also mirrors surveillance gaps. Without national toxicovigilance, the true burden remains unknown.

The international comparison offers a roadmap. Sri Lanka dramatically reduced pesticide suicide deaths through progressive restrictions on highly hazardous products, strong regulation and community awareness campaigns. Bangladesh banned World Health Organization Class I pesticides without harming agricultural output, and China reported improved outcomes following stricter pesticide controls. Meanwhile, researchers in Europe, Asia and North America are exploring experimental adjuncts, including bioscavengers, antioxidants, neuroprotective agents and extracorporeal toxin removal, though none are yet standard of care. For Nigeria, the review’s priorities are more fundamental: mandatory child-resistant packaging and clear toxicity labelling, regional poison control centres, toxicology training in medical curricula, a national treatment protocol, reliable atropine and pralidoxime supply, expanded critical care capacity, and mental health support for at-risk youth. With nearly a quarter of poisoned patients dying from a treatable condition, the authors argue, the gap between available science and delivered care has become a matter of life and death.

Beyond the immediate cholinergic crisis, clinicians managing organophosphate poisoning must remain vigilant for later-appearing syndromes that the pooled Nigerian data largely could not capture. The intermediate syndrome, which emerges 24 to 96 hours after exposure, involves weakness of the neck flexors, proximal limb muscles and respiratory muscles, and can precipitate sudden respiratory arrest in patients who appeared to be recovering. Organophosphate-induced delayed neuropathy, a distal symmetric polyneuropathy appearing two to three weeks after exposure, adds a further dimension to follow-up care. Neither syndrome appeared systematically in the Nigerian literature, likely because fragmented follow-up and high early mortality obscure their detection, but both argue for prolonged observation rather than early discharge.

The pharmacology of atropine therapy also deserves emphasis. Effective treatment requires rapid titration to the endpoint of clear chest sounds and adequate oxygenation, often demanding doses far above those used for other indications, sometimes hundreds of milligrams in severe cases. Underdosing, driven by unfamiliarity or supply constraints, is a recognised cause of preventable death, and the review’s finding that atropine appeared in only about half of the contributing studies suggests inconsistent documentation at best. Pralidoxime’s therapeutic window compounds the problem: because acetylcholinesterase undergoes an irreversible ageing reaction that makes the enzyme permanently resistant to reactivation, oximes administered days after exposure offer little benefit, explaining why the imported pralidoxime given on day seven in the documented intensive care case could not meaningfully alter the course.

The predominance of paediatric accidental ingestion fits a broader pattern seen across low- and middle-income settings, where pesticides are stored in unlabeled or repurposed containers and young children explore their environment orally. Epidemiologists refer to this as the accessibility-vulnerability model: highly toxic products within reach of curious toddlers produce predictable epidemics of poisoning. Simple structural interventions, including lockable storage, child-resistant caps and non-lethal decanting prohibitions, have repeatedly reduced paediatric pesticide deaths in comparable settings at minimal cost.

Finally, the review’s reliance on hospital-based studies means its figures almost certainly underestimate the true national burden. Many poisoned patients in rural Nigeria never reach formal care, treated instead by traditional healers or dying at home, and no national poison registry exists to count them. Establishing toxicovigilance would not only clarify the epidemiology but also provide the surveillance infrastructure needed to evaluate whether regulatory measures, once enacted, actually save lives.

Subject of Research: Clinical patterns, management and outcomes of acute organophosphate pesticide poisoning in Nigeria

Article Title: A systematic review of clinical patterns and outcomes of acute organophosphate poisoning in Nigeria

Article References: Ogundipe, T. O., Salau, I. T., Ramon, I., Efundipo, A. O., & Folorunso, Q. A. (2026). A systematic review of clinical patterns and outcomes of acute organophosphate poisoning in Nigeria. Discover Toxicology, 3(1), Article 17. https://doi.org/10.1007/s44339-026-00062-0

Image Credits: AI Generated

DOI: 10.1007/s44339-026-00062-0

Keywords: organophosphate poisoning, Nigeria, dichlorvos, Sniper, Otapiapia, pesticide poisoning, acetylcholinesterase inhibition, atropine, pralidoxime, systematic review, childhood poisoning, suicide prevention